OLMAHealthcare · BiotechnologyOLMA Stock Forecast: Olema Pharmaceuticals, Inc. Price Predictions for 2026-2027
The 12 Wall Street analysts covering Olema Pharmaceuticals, Inc. hold a median 12-month price target of $40 — +254.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 40 of 100 as at 1 Aug 2026 — in the lower half.
OLMA stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Olema Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (70): The business earns solid, repeatable profits on what it owns.
Issuance (24): The company has been issuing shares or taking on financing, diluting existing holders.
The rank is the raw material. Whether the rules would actually own Olema Pharmaceuticals, Inc. — and when they’d sell — is the membership.
OLMA stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on OLMA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +254.6% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 13 May 2026 | Guggenheim | Maintains | Buy | $38 → $35 |
| 27 Mar 2026 | Wolfe Research | Initiates | Peer Perform | — |
| 19 Mar 2026 | Jefferies | Assumes | Buy | $43 → $40 |
| 18 Mar 2026 | Goldman Sachs | Maintains | Buy | — |
| 18 Mar 2026 | JP Morgan | Maintains | Overweight | — |
| 17 Mar 2026 | Citigroup | Maintains | Buy | — |
| 17 Mar 2026 | Guggenheim | Maintains | Buy | — |
| 9 Mar 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 11 Feb 2026 | Stifel | Initiates | Buy | — |
| 7 Jan 2026 | Piper Sandler | Initiates | Overweight | — |
| 7 Jan 2026 | UBS | Initiates | Buy | — |
| 12 Dec 2025 | Citigroup | Maintains | Buy | — |
| 11 Dec 2025 | Goldman Sachs | Maintains | Buy | — |
| 11 Dec 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 11 Dec 2025 | Oppenheimer | Maintains | Outperform | — |
| 21 Nov 2025 | Goldman Sachs | Maintains | Buy | — |
| 18 Nov 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 18 Nov 2025 | JP Morgan | Maintains | Overweight | — |
| 18 Nov 2025 | Oppenheimer | Maintains | Outperform | — |
| 20 Oct 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
OLMA analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Olema Pharmaceuticals, Inc. (OLMA) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −6.1×
- Price / sales
- —
- Price / book
- 2.1×
- EV / EBITDA
- −2.6×
Cheaper than 90% of US stocks
Cheaper than 45% of US stocks
Cheaper than 74% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 35% of US stocks
Higher than 30% of US stocks
- Return on equity
- −42.9%
- Return on assets
- −25.5%
- Dividend yield
- —
Higher than 23% of US stocks
Higher than 16% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
OLMA vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. OLMA appears on the weeks it earns a place.
Frequently asked questions about OLMA stock
What is the OLMA stock price forecast for 2026-2027?
The 12 Wall Street analysts covering Olema Pharmaceuticals, Inc. have a median 12-month price target of $40, with estimates ranging from $23 to $62. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is OLMA stock a buy right now?
Of the 12 analysts covering Olema Pharmaceuticals, Inc., 11 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Olema Pharmaceuticals, Inc. 40 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank OLMA?
As at 1 Aug 2026, Olema Pharmaceuticals, Inc. ranks 40 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (70 of 100).
Will OLMA stock go up?
No one can know that. What the data says: the median 12-month target from 12 analysts implies +254.6% from the last close, and Ticker Nerd's factor model ranks Olema Pharmaceuticals, Inc. 40 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the OLMA stock forecast for 2030?
No analyst covering Olema Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for OLMA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $23 to $62 over the next 12 months.
How has OLMA stock performed over the past year?
Olema Pharmaceuticals, Inc. returned +111.6% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Olema Pharmaceuticals, Inc. do?
Olema Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women's cancers, particularly breast cancer.
About Olema Pharmaceuticals, Inc.
Olema Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women's cancers, particularly breast cancer. Its lead product candidate, palazestrant (OP-1250), is an oral therapy that acts as both a complete estrogen receptor antagonist (CERAN) and a selective estrogen receptor degrader (SERD), designed for patients with recurrent, locally advanced, or metastatic estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Palazestrant is currently in the pivotal Phase 3 OPERA-01 trial as a monotherapy in second- and third-line settings, and in Phase 1/2 trials in combination with CDK4/6 inhibitors like palbociclib and ribociclib, as well as other agents such as PI3Ka inhibitor alpelisib and mTOR inhibitor everolimus. The company is also advancing OP-3136, an orally available small molecule that selectively inhibits KAT6, in Phase 1 trials for ER+/HER2- metastatic breast cancer and other solid tumors. Olema Pharmaceuticals Inc. operates in the oncology sector, addressing unmet needs in endocrine-driven cancers through innovative small molecule approaches. Founded in 2006 and headquartered in San Francisco, California, it emphasizes precision medicines to improve treatment outcomes in high-incidence markets.
CEO Dr. Sean P. Bohen M.D., Ph.D. · 137 employees · United States · https://olema.com